Beyond glycemic control: Roles for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney disease
Open Access
- 15 June 2025
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 16 (6) , 104706
Abstract
The global prevalence of diabetes has surged in recent years, with diabetic kidney disease (DKD) emerging as a major complication. Traditional therapies have had limited success in slowing progression to end-stage kidney disease. However, novel therapies, particularly sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, which were initially developed for hyperglycemia management, have transformed the treatment of obesity, heart failure, cardiovascular disease, and more recently, DKD. SGLT2 inhibitors have consistently and significantly reduced cardiovascular events, albuminuria, and glomerular filtration rate, highlighting their efficacy across diverse clinical presentations for patients with kidney impairment. Although fewer studies have specifically investigated GLP-1 receptor agonists in patients with kidney disease, existing evidence underscores their potential to slow renal disease progression, reduce albuminuria, and improve clinically relevant outcomes. However, further research is needed to better identify patients most likely to benefit from treatment. Together, these therapies represent valuable advancements for DKD, offering significant reductions in morbidity and mortality and shifting the management of the disease by becoming essential pillars for the treatment of these patients.Keywords
This publication has 193 references indexed in Scilit:
- Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetesCochrane Database of Systematic Reviews, 2024
- Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight LossJAMA, 2023
- Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetesDiabetologia, 2023
- Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease: a systematic review and meta-analysisInternational Urology and Nephrology, 2023
- SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world studyDiabetologia, 2023
- Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in TaiwanJAMA Network Open, 2023
- Effects of GLP‐1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta‐analysisPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2022
- Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes MellitusJAMA Internal Medicine, 2016
- Effect of Finerenone on Albuminuria in Patients With Diabetic NephropathyJAMA, 2015
- GLP‐1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging AgentsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2014